Vistagen Therapeutics, Inc. (VTGN)
NASDAQ: VTGN · Real-Time Price · USD
0.702
+0.085 (13.85%)
At close: Jun 26, 2026, 4:00 PM EDT
0.740
+0.038 (5.41%)
After-hours: Jun 26, 2026, 7:59 PM EDT
Vistagen Therapeutics Stock Forecast
Stock Price Forecast
The 1 analyst with a 12-month price forecast for Vistagen Therapeutics stock has a target of 1.00, which predicts an increase of 42.45% from the current stock price of 0.70.
Analyst Consensus: Hold
* Price targets were last updated on Feb 13, 2026.
Analyst Ratings
The average analyst rating for Vistagen Therapeutics stock from 4 stock analysts is "Hold". This means that analysts believe this stock is likely to perform similarly to the overall market.
Recommendation Trends
| Rating | Dec '25 | Feb '26 | Mar '26 | Apr '26 | May '26 | Jun '26 |
|---|---|---|---|---|---|---|
| Strong Buy | 0 | 0 | 0 | 0 | 0 | 0 |
| Buy | 0 | 0 | 0 | 0 | 0 | 0 |
| Hold | 5 | 5 | 5 | 5 | 5 | 4 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 5 | 5 | 5 | 5 | 5 | 4 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| William Blair | William Blair | Hold Maintains n/a | Hold | Maintains | n/a | n/a | Jun 16, 2026 |
| Stifel Nicolaus | Stifel Nicolaus | Hold Maintains $1 | Hold | Maintains | $1 | +42.45% | Feb 13, 2026 |
Financial Forecast
Revenue This Year
475.00K
from 1.27M
Decreased by -62.57%
Revenue Next Year
3.50M
from 475.00K
Increased by 636.84%
EPS This Year
-1.48
from -1.83
EPS Next Year
-1.11
from -1.48
Revenue Forecast
| Revenue | 2027 | 2028 | 2029 |
|---|---|---|---|
| High | 1.9M | 7.0M | |
| Avg | 475,000 | 3.5M | |
| Low | n/a | n/a |
Revenue Growth
| Revenue Growth | 2027 | 2028 | 2029 |
|---|---|---|---|
| High | 49.7% | 1,373.7% | |
| Avg | -62.6% | 636.8% | |
| Low | -100.0% | -100.0% |
EPS Forecast
| EPS | 2027 | 2028 | 2029 |
|---|---|---|---|
| High | -1.45 | -0.68 | |
| Avg | -1.48 | -1.11 | |
| Low | -1.50 | -1.54 |
EPS Growth
| EPS Growth | 2027 | 2028 | 2029 |
|---|---|---|---|
| High | - | - | |
| Avg | - | - | |
| Low | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.